alt news

29th September 2021

Diaprost Licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer.

The terms of an exclusive License Agreement, inclusive of an upfront payment and potential development and regulatory milestone payments over the life of the agreement, may exceed US$125 million. Diaprost announced today that it has agreed terms for an exclusive Licensing Agreement with Radiopharm Theranostics (RAD); an Australian based biotech startup, focused on building an […]

22nd February 2021

Diaprost Announces Promising New Study for Patients with Metastatic PCa

Diaprost announced today a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost’s propriety antibody (hu5A10) targeting PSA. This rigorous preclinical evaluation of radiolabeled hu5A10-based […]

25th August 2020

Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center

Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer. Press release Diaprost August 25 Pressmeddelande Diaprost 25 augusti

21st January 2020

Diaprost announces Exercise of Option under the terms of its Research and Option Agreement with a leading Pharmaceutical company

Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody. Press release Diaprost jan 21 2020

2nd October 2018

New publication expanding the application of Diaprost antibodies

Read article

4th October 2017

Diaprost announces a Research and Option Agreement with a leading Pharmaceutical company

Diaprost have agreed terms for an exclusive Research and Option Agreement, inclusive of an upfront payment, research funding and potential development milestone payments for its h11B6 antibody for prostate cancer. Pressmeddelande Diaprost 4 okt 2017 Press release Diaprost oct 4 2017

10th January 2017

Dan Thorek presents the latest results in BBC-podcast

Listen to podcast

4th January 2017

More Precise Imaging of Prostate Cancer Could Give Insight into Drug Effectiveness

Read article

13th December 2016

Study demonstrates the feasibility of targeting human kallikrein-related peptidase 2 (hK2) for detection and monitoring of prostate cancer

A new publication in Science Translational Medicine demonstrates that in vivo targeting of the enzyme human kallikrein-related peptidase 2 (hK2) is a powerful tool that can be used for detection of prostate cancer and monitoring treatment by quantifying the activity of the androgen receptor pathway. Pressmeddelande Diaprost 13 dec 2016 Press release Diaprost dec 13 […]